Maintenance Niraparib Given at Individualized Starting Dose Improves PFS in Ovarian Cancer
March 20th 2022
When maintenance niraparib was administered at an individualized starting dose, it resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, irrespective of biomarker status.